ClinicalTrials.gg

Program

sarecycline

Also written as “Sarecycline”, “50 mg P005672-HCl” and “100 mg P005672-HCl”.

Its studies are mostly in Acne Vulgaris, led by 2 companies.

Furthest: phase 4, since Dec 15, 20145 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Almirall40 open or runningphase 3since Dec 15, 2014Jun 22, 2012none ahead
Integrative Skin Science and Research11 open or runningphase 4since Apr 15, 2026Apr 15, 2026Apr 2027phase 4 · NCT07544251

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2012First study: phase 2 study in Acne VulgarisNew to AlmirallAlmirall · NCT01628549 · 285 enrolled · United States
  2. Dec 15, 20142 phase 3 studies in Acne VulgarisAlmirall · NCT02322866, NCT02320149
  3. Apr 2, 2015Phase 3 study in Acne VulgarisAlmirall · NCT02413346 · 490 enrolled · United States
  4. Apr 15, 2026Integrative Skin Science and Research's first study: phase 4 study in Acne VulgarisNew to Integrative Skin Science and ResearchIntegrative Skin Science and Research · NCT07544251 · 30 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 4 study in Acne VulgarisIntegrative Skin Science and Research · NCT07544251

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07544251Acne Vulgaris · United States4RecruitingIntegrative Skin Science and ResearchApr 202730
NCT02413346Acne Vulgaris · United States3CompletedAlmirallAug 26, 2016490
NCT02322866Acne Vulgaris · United States3CompletedAlmirallJan 12, 20171,034
NCT02320149Acne Vulgaris · United States3CompletedAlmirallFeb 1, 2017968
NCT01628549Acne Vulgaris · United States2CompletedAlmirallNov 16, 2012285

How it is read

Names in the registry

  • “Sarecycline”, 4 entries
  • “50 mg P005672-HCl”, 1 entry
  • “100 mg P005672-HCl”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.